Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 450
- Registration Number
- NCT01450553
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Martin Memorial Treasure Coast Surgeons, Stuart, Florida, United States
🇺🇸Cardio-Thoracic Surgeons, P. C., Birmingham, Alabama, United States
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
- Conditions
- Solid Organ Tumors
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 167
- Registration Number
- NCT01271959
- Locations
- 🇺🇸
The Center For Gynecologic Oncology, Hollywood, Florida, United States
🇺🇸Oncology Associates of West Kentucky, Paducah, Kentucky, United States
🇺🇸Albany Thoracic & Esophageal Surgery, Albany, New York, United States
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
- Conditions
- Ovarian CancerPeritoneal CancerFallopian Tube Cancer
- Interventions
- Other: ChemoFx
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 512
- Registration Number
- NCT01048814
- Locations
- 🇺🇸
Precision Therapeutics, Inc., Pittsburgh, Pennsylvania, United States
Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients
- Conditions
- Endometrial Cancer
- Interventions
- Other: ChemoFx
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT01049126
- Locations
- 🇺🇸
Precision Therapeutics, Inc., Pittsburgh, Pennsylvania, United States
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT01007890
- Locations
- 🇺🇸
Advanced Medical Specialties, Miami, Florida, United States
🇺🇸Breastlink Medical Group, Inc, Long Beach, California, United States
🇺🇸Morristown Memorial Hospital, Morristown, New Jersey, United States
ChemoFx® PRO - A Post-Market Data Collection Study
- Conditions
- Peritoneal CancerVaginal CancerVulvar CancerFallopian Tube CancerCervical CancerOvarian CancerEndometrial CancerUterine Neoplasms
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 2756
- Registration Number
- NCT00669422
- Locations
- 🇺🇸
Sinai Hospital, Baltimore, Maryland, United States
🇺🇸OSU Gynecologic Oncology, Columbus, Ohio, United States
🇺🇸North Texas Gynecologic Oncology, Dallas, Texas, United States
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 256
- Registration Number
- NCT00288275
- Locations
- 🇺🇸
Rush University, Chicago, Illinois, United States
🇺🇸University of California, Irvine, California, United States
🇺🇸Kaiser Permanente, Los Angeles, California, United States